biostudies-literatureDuring JThelma Zoega FoundationEuropean Clinical Research Infrastructures NetworkHans-Gabriel and Alice Trolle-Wachtmeister Foundation for Medical ResearchSwedish Heart Lung FoundationThe Torsten Söderberg foundation at the Royal Swedish Academy of SciencesThe Swedish Brain FoundationLions Research fund SkåneSwedish Research CouncilLundbeck FoundationThe Koch FoundationTrygFondenArbetsmarknadens FörsäkringsaktiebolagThe County Council of SkåneStig and Ragna Gorthon FoundationSkåne University Hospital Foundations, the Gyllenstierna-Krapperup Foundation, and governmental funding of clinical research within the Swedish National Health SystemThure Carlsson FoundationLundbeckfondenThe Swedish Society of MedicineSouth Swedish Hospital Region Research Funds185https://www.ebi.ac.uk/biostudies/studies/S-EPMC7189642biostudies-literatureUnknown24(1)<h4>Background</h4>Arginine vasopressin has complex actions in critically ill patients, involving vasoregulatory status, plasma volume, and cortisol levels. Copeptin, a surrogate marker for arginine vasopressin, has shown promising prognostic features in small observational studies and is used clinically for early rule out of acute coronary syndrome. The objective of this study was to explore the association between early measurements of copeptin, circulatory status, and short-term survival after out-of-hospital cardiac arrest.<h4>Methods</h4>Serial blood samples were collected at 24, 48, and 72 h as part of the target temperature management at 33 °C versus 36 °C after cardiac arrest trial, an international multicenter randomized trial where unconscious survivors after out-of-hospital cardCritical care (London, England)Copeptin as a marker of outcome after cardiac arrest: a sub-study of the TTM trial.PMC7189642R186-2015-2132NA134281, 296161, 286321M2010/1837, M2010/1641, 35330110000120090275Wise MHorn JWanscher MJHassager CDuring JDevaux YUnden JAnnborn MDankiewicz JNielsen NFriberg HCronberg TStammet PKuiper MKjaergaard JNikoukhah HRfalseCopeptin as a marker of outcome after cardiac arrest: a sub-study of the TTM trial.<h4>Background</h4>Arginine vasopressin has complex actions in critically ill patients, involving vasoregulatory status, plasma volume, and cortisol levels. Copeptin, a surrogate marker for arginine vasopressin, has shown promising prognostic features in small observational studies and is used clinically for early rule out of acute coronary syndrome. The objective of this study was to explore the association between early measurements of copeptin, circulatory status, and short-term survival after out-of-hospital cardiac arrest.<h4>Methods</h4>Serial blood samples were collected at 24, 48, and 72 h as part of the target temperature management at 33 °C versus 36 °C after cardiac arrest trial, an international multicenter randomized trial where unconscious survivors after out-of-hospital card2020-01-01T00:00:00Z2020 Apr2026-05-01T03:24:36.801Z2020-05-22T19:10:45ZS-EPMC71896423234535610.1186/s13054-020-02904-8